ANAB
AnaptysBio, Inc.
There isn't enough reported data to score ANAB yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ANAB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Strong |
ANAB's balance sheet is currently strong, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ANAB PE Valuation
ANAB has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 5.3x next year's earnings.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ANAB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ANAB to return to profit, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ANAB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.01 | — |
| Q1 2026 | -$1.02 | +$3.74 |
| Q4 2025 | -$0.46 | +$4.66 |
| Q3 2025 | -$2.73 | +$3.35 |
| Q2 2025 | -$4.39 | +$1.96 |
| Q1 2025 | -$4.76 | +$1.38 |
| Q4 2024 | -$5.12 | +$0.96 |
| Q3 2024 | -$6.08 | -$0.66 |
| Q2 2024 | -$6.35 | -$1.16 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 121% for ANAB versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
ANAB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30.3M | -60% |
| Q1 2026 | $25.6M | -8% |
| Q4 2025 | $108.2M | +151% |
| Q3 2025 | $76.3M | +154% |
| Q2 2025 | $22.3M | +103% |
| Q1 2025 | $27.8M | +287% |
| Q4 2024 | $43.1M | +379% |
| Q3 2024 | $30M | +805% |
LLY has the stronger quarterly revenue trend. Revenue is up 36% for ANAB versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +20 points |
| Q1 2026 | -136% | -36 points |
| Q4 2025 | 62% | +84 points |
| Q3 2025 | 45% | +121 points |
| Q2 2025 | -118% | +250 points |
| Q1 2025 | -99% | +489 points |
| Q4 2024 | -22% | +446 points |
| Q3 2024 | -76% | +1061 points |
ANAB has the edge over LLY on profitability, with a higher operating margin.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
ANAB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.5M | +$17.8M |
| Q1 2026 | -$25.9M | -$15.2M |
| Q4 2025 | $98M | +$164.9M |
| Q3 2025 | -$27.4M | -$17.2M |
| Q2 2025 | -$40.3M | -$18.9M |
| Q1 2025 | -$10.7M | +$26.5M |
| Q4 2024 | -$66.9M | -$32.3M |
| Q3 2024 | -$10.1M | +$26.5M |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with ANAB at up 149%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
ANAB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +22% | +6.4M shares |
| 1 year | +22% | +6.3M shares |
| 3 years | +32% | +8.4M shares |
| 5 years | +28% | +7.7M shares |
| Available history | +30% | +8M shares |
ANAB has 35M diluted shares, up 22% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $3.4M |
| Q3 2025 | $9.7M |
| Q2 2025 | $51.1M |
| Q1 2025 | $4.4M |
| Q4 2024 | $456,000 |
| Q3 2024 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ANAB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ANAB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -6.0x | Net Cash |
| Q4 2025 | -4.9x | Net Cash |
| Q3 2021 | -40.6x | Net Cash |
ANAB has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ANAB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.4 | Neutral |
| Stochastic | 21.4 | Neutral |
ANAB's weekly RSI is 45 (neutral) and its Stochastic is 21 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ANAB PE vs Healthcare Sector
| Metric | ANAB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ANAB has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ANAB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $47.9 | 0.3% below |
| 20 week MA | $53.7 | 11% below |
| 50 week MA | $47.7 | 0.1% above |
| 100 week MA | $31.5 | 52% above |
| 200 week MA | $23.5 | 103% above |
ANAB has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 103% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ANAB on trend strength, trading above more of its moving averages.
ANAB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.2 | $14.8 | +33% |
| 2021 | $14.8 | $24.7 | +67% |
| 2022 | $24.7 | $19.5 | -21% |
| 2023 | $19.5 | $14.3 | -27% |
| 2024 | $14.3 | $8.69 | -39% |
| 2025 | $8.69 | $33.4 | +284% |
| 2026 YTD | $33.4 | $47.8 | +43% |
ANAB has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.